Skip to main content
Clinical Trials/RBR-9tpwc5
RBR-9tpwc5
Completed
未知

The effect of Conventional Transcutaneous Electric Nerve Stimulation for treatment of Migraine crisis: a randomized clinical trial

Faculdade de Medicina de Botucatu da Universidade Estadual Paulista0 sitesMay 4, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
Migraine with and without aura
Sponsor
Faculdade de Medicina de Botucatu da Universidade Estadual Paulista
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 4, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
Faculdade de Medicina de Botucatu da Universidade Estadual Paulista

Eligibility Criteria

Inclusion Criteria

  • The selection of patients will be carried out based on electronic medical record research and routine consultations in the head and face ambulatory, following the Guidelines for clinical trials of drug in migraine (IHS, 2012\). Patients with a diagnosis of primary headache classified as migraine will be included; And the major subtypes: migraine with aura and migraine without aura; (ICHD\-III, 2013\), respecting the following criteria:
  • Migraine without aura: recurrent cephalic disorder in at least five episodes with the following characteristics: duration of 4 to 72 hours, unilateral, pulsatile, moderate or severe intensity, aggravation by routine physical activity and association with nausea and / or photophobia and phonophobia ;Migraine with aura: at least five episodes with features of migraine without aura and preceded or accompanied by neural symptoms. The typical aura occurs from 5 to 60 minutes duration before the onset of pain, unilateral and completely reversible, with visual, sensory or other central nervous system symptoms that usually develop gradually and are usually followed by Headaches with migraine characteristics and associated symptoms. It can be of six different types, namely retinal aura, visual aura, sensory\-somesthetic aura, motor aura, aphasic aura and brainstem aura.
  • The study will invite patients of both genders, aged between 18 and 65 years, age at onset of illness less than 50 years, diagnosed with migraine for at least one year before being recruited to participate in the study. All should be in current treatment with the use of recommended medicines, in stable doses for at least 30 days and that present sporadic crises.The use of these recommended drugs in the literature and guidelines for the prevention of migraine will occur in conventional doses. All predicted classes of drugs may be employed, namely: calcium channel blockers, such as nimodipine, beta\-blockers, such as propranolol and atenolol; Tricyclic antidepressants, such as amitriptyline and nortriptyline; And, among the anticonvulsants, only topiramate and sodium valproate. The frequencies of migraine attacks (with the use of the recommended treatment and in stable doses) should be 1 to 6 times a month, with a remission period of at least 48 hours (IHS, 2012\).

Exclusion Criteria

  • Patients with the following criteria will be excluded from the sample: Physical or intellectual incapacity to respond to the survey questionnaire, illiterate, diabetic, pacemaker, epileptic, users of illicit substances and those diagnosed with other CNS diseases (IHS, 2012\). Other classifications of migraine, such as chronic migraine (over 15 days with headache / month) and overuse of medications, eg, more than 10 days in the use of triptans for acute pain (IHS, 2012\).
  • Ethical patients, ie the acceptable consumption of alcoholic beverages is up to 15 doses / week for men, not exceeding three daily doses and 10 doses / week for women, no more than two doses per day (WHO, 2004\).

Outcomes

Primary Outcomes

Not specified

Similar Trials